OverviewChartNewsTraderScreen

L&S Knock-Out AYJ 09.12.2024/  DE000LX30TD5  /

Lang & Schwarz
5/23/2024  2:22:17 PM Chg.+0.04 Bid2:22:17 PM Ask2:22:17 PM Underlying Strike price Expiration date Option type
1.27EUR +3.25% 1.27
Bid Size: -		 1.32
Ask Size: -		 VALNEVA SE EO... 3.00 EUR 12/9/2024 Call
GlobeNewswire 5/21 Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
GlobeNewswire 5/13 Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya...
GlobeNewswire 5/7 Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire 3/26 Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
GlobeNewswire 3/25 Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
GlobeNewswire 3/21 Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th Wo...
GlobeNewswire 3/20 Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire 3/18 Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and Orbi...
GlobeNewswire 3/4 Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
GlobeNewswire 2/29 U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHI...
GlobeNewswire 2/15 Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
GlobeNewswire 2/5 Valneva Announces Sale of Priority Review Voucher for $103 Million
GlobeNewswire 1/10 Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
GlobeNewswire 1/4 Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Foru...
GlobeNewswire 12/29/2023 Valneva Provides Updated 2023 Financial Guidance
GlobeNewswire 12/4/2023 Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, ...
GlobeNewswire 12/4/2023 Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine ...
GlobeNewswire 11/27/2023 EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assess...
GlobeNewswire 11/15/2023 Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including ...
GlobeNewswire 11/13/2023 Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chik...
GlobeNewswire 11/10/2023 Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®
GlobeNewswire 11/9/2023 Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
GlobeNewswire 11/7/2023 Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update
GlobeNewswire 11/7/2023 Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
GlobeNewswire 10/25/2023 Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Asse...